Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lower-dose versus standard-dose oral TMP/SMX for melioidosis eradication therapy
ACTRN12625001247460Phase 4Recruiting
- Sponsor
- Cairns Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of trimethoprim + sulfamethoxazole in melioidosis (2 arms), sponsored by Cairns Hospital. Primary endpoint: Culture-confirmed recrudescence or relapse of melioidosis. Started Jan 2026; status: recruiting.
02
Drugs
trimethoprim + sulfamethoxazole
03
Conditions
melioidosis
Beyond the preview
Go deeper on ACTRN12625001247460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001247460.